Description: Firebrick Pharma Limited, a pharmaceutical company, develops and commercializes nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Home Page: www.firebrickpharma.com
FRE Technical Analysis
NUVEEN INVESTMENT FUNDS INC
,
Phone:
1300 301 874
Officers
| Name | Title |
|---|---|
| Dr. Peter Laurence Molloy BSc, FAICD, MBA | Founder, Exec. Chairman & CEO |
| Dr. Stephen Francis Goodall MASc, MBA | Founder, COO & Exec. Director |
| Mr. Kavi Bekarma B.Sc., C.A. | Chief Financial Officer |
| Dr. Simon Tucker | Chief Scientific Officer |
| Ms. Robyn Branigan | Head of Marketing |
| Prof. Peter Friedland | Chief Medical Officer |
| Dr. Monique Baldwin | Head of Regulatory Affairs |
| Ms. Kyla Garic | Exec. Officer |
| Mr. Stephen Buckley | Company Sec. |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.8027 |
| Price-to-Sales TTM: | 37.4846 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |